Mysthera Therapeutics, a Basel, Switzerland-based company developing oral therapeutics to treat complex autoimmune diseases, raised $3.5M in Seed funding from Forty51 Ventures.
The company will use the funds to advance its portfolio of pre-clinical stage, pan-PIM kinase inhibitors to modulate multi-lineage immune cell functions. PIM kinases are gateway kinases in multiple immune cell lineages that drive excessive inflammation. PIM kinase inhibition selectively modulates immune cell function in multiple lineages associated with complex disease.
Mysthera Therapeutics is led by CEO Darren Cunningham and SVP R&D Dr. Stefan Haak. The company's pipeline includes pre-clinical stage, PIM kinase inhibitors in-licensed from Inflection Biosciences Ltd.
